Evaluation of Ferritin and Transferrin Ratio as a Prognostic Marker for Hepatocellular Carcinoma
- PMID: 32128703
- DOI: 10.1007/s12029-020-00373-4
Evaluation of Ferritin and Transferrin Ratio as a Prognostic Marker for Hepatocellular Carcinoma
Abstract
Purpose of the study: Hepatocellular carcinoma (HCC) has tripled in incidence over the past 20 years and now ranks as the third leading cause of mortality attributed to cancer. Underlying pathophysiology is sustained hepatic inflammation which results in hepatocellular dysplasia and thus an environment prone to HCC. Considering the essential role of inflammation in the pathogenesis of HCC, we evaluated the prognostic utility of ferritin-transferrin ratio (FTR) in HCC.
Methods: We retrospectively reviewed the electronic medical records of patients with HCC (diagnosed on radiographic criteria and/or biopsy) from 2000 through 2015. We collected data regarding the patient demographics, laboratory investigations at the time of HCC diagnosis and prior to the initiation of treatment. Overall survival was calculated from the time of diagnosis, cases were censored at the date of last follow-up, if date of death was not known. Kaplan-Meier curves were estimated to evaluate the prognostic significance of FTR. Receiver operating characteristics (ROC) curve was plotted for FTR to predict mortality and identify cut-off value by optimized Youden's index.
Results: Among the 176 patients identified by initial screening, 116 patients were eventually included for analysis. Overall median survival was 11.9 months. FTR, of note, was significantly lower in alive (6.9, p < 0.001). In univariate analysis, alfa-fetoprotein (AFP), aspartate aminotransferase (AST), serum ferritin (SF), transferrin (TFS), and FTR were significantly associated with mortality. On multivariate analysis for mortality, FTR, AFP, and epidemiologic factors predictive of mortality including male gender and advanced HCC were significant.
Conclusion: The ferritin-transferrin ratio (FTR), calculated at the time of HCC diagnosis could predict mortality in our cohort of patients. With an optimal cut-off of 7.7 for FTR were stratified into high- and low-risk groups. The hazard ratio between the two groups was 2.36 (p < 0.003). Future studies with longitudinal follow-up of FTR at intervals and important time points (e.g., perioperative) might provide more insights to its prognostic value.
Keywords: AFP; FTR; Ferritin transferrin ratio; HCC; SF; Serum ferritin; Transferrin TFS.
Similar articles
-
Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.World J Gastroenterol. 2015 May 14;21(18):5607-21. doi: 10.3748/wjg.v21.i18.5607. World J Gastroenterol. 2015. PMID: 25987786 Free PMC article.
-
Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.Oncotarget. 2016 Nov 1;7(44):72276-72289. doi: 10.18632/oncotarget.10848. Oncotarget. 2016. PMID: 27472390 Free PMC article.
-
Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma.Br J Surg. 2016 May;103(6):716-724. doi: 10.1002/bjs.10093. Epub 2016 Mar 21. Br J Surg. 2016. PMID: 26996727
-
Preoperative serum ferritin is an independent prognostic factor for liver cancer after hepatectomy.Surg Oncol. 2019 Jun;29:159-167. doi: 10.1016/j.suronc.2019.05.013. Epub 2019 May 21. Surg Oncol. 2019. PMID: 31196483
-
Emerging biomarkers in HCC patients: Current status.Int J Surg. 2020 Oct;82S:70-76. doi: 10.1016/j.ijsu.2020.04.043. Epub 2020 Apr 25. Int J Surg. 2020. PMID: 32344023 Review.
Cited by
-
Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review.World J Surg Oncol. 2025 Apr 26;23(1):166. doi: 10.1186/s12957-025-03765-7. World J Surg Oncol. 2025. PMID: 40287734 Free PMC article. Review.
-
Development and Validation of a Nomogram for Predicting Survival Based on Ferritin and Transferrin Ratio in Breast Cancer Patients.Cancer Control. 2024 Jan-Dec;31:10732748241261553. doi: 10.1177/10732748241261553. Cancer Control. 2024. PMID: 38850515 Free PMC article.
-
Generation of bioluminescent enzyme immunoassay for ferritin by single-chain variable fragment and its NanoLuc luciferase fusion.Anal Bioanal Chem. 2022 Sep;414(23):6939-6946. doi: 10.1007/s00216-022-04261-7. Epub 2022 Aug 10. Anal Bioanal Chem. 2022. PMID: 35945290 Free PMC article.
References
-
- Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: a comprehensive review. World J Hepatol. 2015;7:2648–63. https://doi.org/10.4254/wjh.v7.i26.2648 . - DOI - PubMed - PMC
-
- Cai J, Li B, Zhu Y, Fang X. Prognostic biomarker identification through integrating the gene signatures of hepatocellular Carcinoma properties. EBioMedicine. 2017;19:18–30. https://doi.org/10.1016/j.ebiom.2017.04.014 . - DOI - PubMed - PMC
-
- Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer. 2005;92:1862–8. https://doi.org/10.1038/sj.bjc.6602590 . - DOI - PubMed - PMC
-
- Villanueva A. Hepatocellular Carcinoma. NEJM. 2019;380:1450–62. https://doi.org/10.1056/NEJMc1906565 . - DOI - PubMed
-
- Wang Y, Attar BM. Evaluation of the prognostic value of platelet to lymphocyte ratio in patients with hepatocellular carcinoma. J Gastrointest Oncol. 2017;8(6):1065–71. https://doi.org/10.21037/jgo.2017.09.06 . - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous